The World Health Organization has approved the use of the first malaria vaccine, called Mosquirix.
The vaccine that is safe, moderate and ready for distribution, is a historic event, said Dr. Pedro Alonso, director of its Global Malaria Program.
Pharmaceutical company GlaxoSmithKline decided to approve the vaccine, first developed in 1987. Decision carries out after reviewing a pilot program that has been deployed in Ghana, Kenya and Malawi since 2019. It has been given more than two million doses.
In sub-Saharan Africa and other areas where mild to moderate malaria transmission observed is recommended the vaccine for children.
However, funding is an important step ahead of the delivery of the vaccine to African children.
The vaccine significantly reduces malaria and fatal malaria in children. It is the first vaccine to have completed clinical development and received positive scientific feedback from the regulatory body, the European Medicines Agency.
